Ernest H. Law

1.4k total citations · 1 hit paper
64 papers, 738 citations indexed

About

Ernest H. Law is a scholar working on Urology, Dermatology and Oncology. According to data from OpenAlex, Ernest H. Law has authored 64 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Urology, 15 papers in Dermatology and 15 papers in Oncology. Recurrent topics in Ernest H. Law's work include Hair Growth and Disorders (23 papers), Advanced Breast Cancer Therapies (11 papers) and Dermatology and Skin Diseases (9 papers). Ernest H. Law is often cited by papers focused on Hair Growth and Disorders (23 papers), Advanced Breast Cancer Therapies (11 papers) and Dermatology and Skin Diseases (9 papers). Ernest H. Law collaborates with scholars based in United States, United Kingdom and Germany. Ernest H. Law's co-authors include A. Simon Pickard, Ruixuan Jiang, Feng Xie, James W. Shaw, Cynthia L. Gong, Jan J.V. Busschbach, Kristina S. Boye, Alan Balch, Mark Oppe and Eleanor Pullenayegum and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Ernest H. Law

57 papers receiving 732 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

United States Valuation of EQ-5D-5L Health States Using an International Protocol

2019 251 citations A. Simon Pickard, Ernest H. Law et al. Value in Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ernest H. Law United States	13	246	130	100	98	77	64	738
Roberta Ciampichini Italy	12	190 0.8×	182 1.4×	68 0.7×	102 1.0×	135 1.8×	40	733
David Phillippo United Kingdom	16	221 0.9×	133 1.0×	47 0.5×	104 1.1×	58 0.8×	29	1.1k
John Coombs United States	17	110 0.4×	289 2.2×	74 0.7×	150 1.5×	51 0.7×	45	1.4k
Anthony J. Hatswell United Kingdom	17	338 1.4×	204 1.6×	80 0.8×	69 0.7×	37 0.5×	65	826
Dasha Cherepanov United States	15	69 0.3×	97 0.7×	82 0.8×	81 0.8×	58 0.8×	32	766
Inge R. Konings Netherlands	17	72 0.3×	453 3.5×	58 0.6×	220 2.2×	39 0.5×	42	1.0k
Jörg Ruof Germany	21	401 1.6×	39 0.3×	160 1.6×	46 0.5×	51 0.7×	67	1.4k
Zhongyun Zhao United States	21	273 1.1×	527 4.1×	130 1.3×	190 1.9×	53 0.7×	77	1.2k
Alison Hall United Kingdom	21	73 0.3×	143 1.1×	95 0.9×	166 1.7×	70 0.9×	63	1.2k
Sangjin Shin South Korea	12	120 0.5×	54 0.4×	92 0.9×	44 0.4×	62 0.8×	27	591

Countries citing papers authored by Ernest H. Law

Since Specialization

Citations

This map shows the geographic impact of Ernest H. Law's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernest H. Law with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernest H. Law more than expected).

Fields of papers citing papers by Ernest H. Law

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernest H. Law. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernest H. Law. The network helps show where Ernest H. Law may publish in the future.

Co-authorship network of co-authors of Ernest H. Law

This figure shows the co-authorship network connecting the top 25 collaborators of Ernest H. Law. A scholar is included among the top collaborators of Ernest H. Law based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernest H. Law. Ernest H. Law is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Law, Ernest H., Bintu Sherif, Arash Mostaghimi, et al.. (2025). Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3. International Journal of Dermatology. 65(3). 526–534.

Law, Ernest H., et al.. (2025). Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial. Journal of Dermatological Treatment. 36(1). 2460577–2460577. 1 indexed citations

Anderson, Peter, et al.. (2024). Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe. Dermatology and Therapy. 14(12). 3243–3258. 1 indexed citations

Sinclair, Rodney, Ernest H. Law, Xingqi Zhang, et al.. (2024). Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3. Dermatology. 240(5-6). 1–11. 2 indexed citations

Lloyd, Andrew, et al.. (2024). Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata. PharmacoEconomics - Open. 8(5). 715–725.

Aceituno, David, et al.. (2024). Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. Journal of the European Academy of Dermatology and Venereology. 39(6). 1134–1142. 9 indexed citations

Tervonen, Tommi, Chiara Whichello, Ernest H. Law, et al.. (2023). Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment. The Journal of Dermatology. 51(2). 243–252. 4 indexed citations

Taylor‐Stokes, Gavin, et al.. (2022). Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study. Clinical Therapeutics. 44(12). 1588–1601. 11 indexed citations

Law, Ernest H., Achim Wöckel, Rohan Parikh, et al.. (2022). Abstract OT2-19-04: European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Cancer Research. 82(4_Supplement). OT2–19. 1 indexed citations

10.

Law, Ernest H., et al.. (2021). Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. Journal of Comparative Effectiveness Research. 11(2). 109–120. 5 indexed citations

11.

Law, Ernest H., et al.. (2021). Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis. The Breast. 57. 5–17. 40 indexed citations

12.

Zhou, Jifang, Naomi Y. Ko, Kent Hoskins, et al.. (2021). Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race. The Breast. 59. 367–375. 6 indexed citations

13.

Criscitiello, Carmen, Dean Spurden, James Piercy, et al.. (2021). Health-Related Quality of Life Among Patients With HR+/HER2– Early Breast Cancer. Clinical Therapeutics. 43(7). 1228–1244.e4. 17 indexed citations

14.

Beusterien, Kathleen, et al.. (2021). Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment. Patient Preference and Adherence. Volume 15. 611–623. 12 indexed citations

15.

Rencz, Fanni, Valentin Brodszky, László Gulàcsi, et al.. (2020). Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Value in Health. 23(9). 1235–1245. 72 indexed citations

16.

Criscitiello, Carmen, Dean Spurden, A. Rider, et al.. (2020). 82P A multinational study of real-world treatment patterns among patients with early stage HR+/HER2- breast cancer (BC). Annals of Oncology. 31. S42–S43. 2 indexed citations

17.

Jiang, Ruixuan, et al.. (2018). Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis. Diabetes Therapy. 9(3). 1021–1036. 7 indexed citations

18.

Law, Ernest H., et al.. (2018). Increasing uptake of comparative effectiveness and patient-centered outcomes research among stakeholders: insights from conference discussion. Journal of Comparative Effectiveness Research. 7(2). 181–191. 8 indexed citations

19.

Law, Ernest H., et al.. (2015). Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Drug Design Development and Therapy. 9. 3557–3557. 1 indexed citations

20.

Law, Ernest H., et al.. (2013). Should Accreditation Canada’s Required Organizational Practices and Standards Lead to Prioritization of Clinical Pharmacy Services over Distribution-Related Medication Safety Strategies?. The Canadian Journal of Hospital Pharmacy. 66(3). 194–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact